A detailed history of Eventide Asset Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Eventide Asset Management, LLC holds 786,990 shares of SNDX stock, worth $12.6 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
786,990
Holding current value
$12.6 Million
% of portfolio
0.27%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.93 - $24.81 $14.1 Million - $19.5 Million
786,990 New
786,990 $15.1 Million
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $15.9 Million - $22.7 Million
-1,165,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$13.87 - $19.8 $6.42 Million - $9.16 Million
462,652 Added 65.87%
1,165,000 $22.3 Million
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $17.6 Million - $33.1 Million
-1,314,645 Reduced 65.18%
702,348 $12.1 Million
Q1 2021

May 14, 2021

BUY
$19.28 - $24.59 $1.37 Million - $1.75 Million
70,993 Added 3.65%
2,016,993 $45.1 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $18.8 Million - $33 Million
1,246,800 Added 178.32%
1,946,000 $43.3 Million
Q3 2020

Nov 13, 2020

BUY
$13.39 - $17.48 $2.77 Million - $3.61 Million
206,700 Added 41.97%
699,200 $10.3 Million
Q2 2020

Aug 14, 2020

BUY
$8.94 - $20.98 $2.38 Million - $5.58 Million
265,820 Added 117.27%
492,500 $7.3 Million
Q1 2020

May 15, 2020

BUY
$6.65 - $12.03 $1.51 Million - $2.73 Million
226,680 New
226,680 $2.49 Million
Q4 2017

Feb 14, 2018

SELL
$7.8 - $12.94 $1.76 Million - $2.91 Million
-225,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.9 - $12.73 $2.45 Million - $2.86 Million
225,000
225,000 $2.63 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.